 | ||||||
| Ebola | ||||||
| NEWS | ||||||
| Oasmia Pharmaceutical AB (OASM) At $0.88 Forms Bottom; 2 Bullish Analysts Covering Novavax ... It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates. Since August 31, 2017, it had 0 buys, and 1 insider sale for $184,870 activity.
| ||||||
| See more results | Edit this alert | ||||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
Tidak ada komentar:
Posting Komentar